Trial Profile
Intrathecal 2-hydroxypropyl-beta-cyclodextrin (HPBCD) therapy in adult-onset Niemann-Pick disease type C (NPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Therapeutic Use
- 09 Dec 2015 New trial record